

9-1-2017

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review

Paul M. Arnold
University of Kansas

James S. Harrop
Thomas Jefferson University

Geno J. Merli
Thomas Jefferson University

Lindsay G. Tetreault
Toronto Western Hospital
Follow this and additional works at: <https://jdc.jefferson.edu/neurosurgeryfp>

 Brain K. Kwon
Part of the [Neurology Commons](#)
University of British Columbia

[Let us know how access to this document benefits you](#)

See next page for additional authors
Recommended Citation

Arnold, Paul M.; Harrop, James S.; Merli, Geno J.; Tetreault, Lindsay G.; Kwon, Brain K.; Casha, Steve; Palmieri, Katherine; Wilson, Jefferson R.; Fehlings, Michael G.; Holmer, Haley K.; and Norvell, Daniel C., "Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review" (2017). *Department of Neurosurgery Faculty Papers*. Paper 91.
<https://jdc.jefferson.edu/neurosurgeryfp/91>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Paul M. Arnold, James S. Harrop, Geno J. Merli, Lindsay G. Tetreault, Brain K. Kwon, Steve Casha, Katherine Palmieri, Jefferson R. Wilson, Michael G. Fehlings, Haley K. Holmer, and Daniel C. Norvell

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review

Paul M. Arnold, MD¹, James S. Harrop, MD², Geno Merli, MD³, Lindsay A. Tetreault, PhD⁴, Brian K. Kwon, MD, PhD⁵, Steve Casha, MD, PhD, FRCSC⁶, Katherine Palmieri, MD¹, Jefferson R. Wilson, MD, PhD^{7,8}, Michael G. Fehlings, MD, PhD, FRCSC, FACS⁴, Haley K. Holmer, MPH⁹, and Daniel C. Norvell, PhD, MPH⁹

Abstract

Study Design: Systematic review.

Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another anticoagulant strategy for preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after acute spinal cord injury (SCI)? (1b) Mechanical prophylaxis strategies alone or in combination with other strategies for preventing DVT and PE after acute SCI? (1c) Prophylactic inferior vena cava filter insertion alone or in combination with other strategies for preventing DVT and PE after acute SCI? (2) What is the optimal timing to initiate and/or discontinue anticoagulant, mechanical, and/or prophylactic inferior vena cava filter following acute SCI? (3) What is the cost-effectiveness of these treatment options?

Methods: A systematic literature search was conducted to identify studies published through February 28, 2015. We sought randomized controlled trials evaluating efficacy and safety of antithrombotic strategies. Strength of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

Results: Nine studies satisfied inclusion criteria. We found a trend toward lower risk of DVT in patients treated with enoxaparin. There were no significant differences in rates of DVT, PE, bleeding, and mortality between patients treated with different types of low-molecular-weight heparin or between low-molecular-weight heparin and unfractionated heparin. Combined anticoagulant and mechanical prophylaxis initiated within 72 hours of SCI resulted in lower risk of DVT than treatment commenced after 72 hours of injury.

Conclusion: Prophylactic treatments can be used to lower the risk of venous thromboembolic events in patients with acute SCI, without significant increase in risk of bleeding and mortality and should be initiated within 72 hours.

Keywords

deep vein thrombosis, pulmonary embolism, spinal cord injury, bleeding, mortality

Introduction

Patients with spinal cord injury (SCI) are at an increased risk of venous thromboembolic (VTE) events due to hypercoagulability, stasis, and intimal injury.¹ Interruption of neurologic impulses and paralysis cause metabolic changes to the blood vessels and altered venous competence such as decreased distensibility and increased flow resistance.² Furthermore, immobilization of the lower extremities results in stagnant blood flow and ultimately the formation of venous thrombi. Patients

¹ University of Kansas, Kansas City, KS, USA

² Thomas Jefferson University, Philadelphia, PA, USA

³ Thomas Jefferson University Hospitals, Philadelphia, PA, USA

⁴ Toronto Western Hospital, Toronto, Ontario, Canada

⁵ University of British Columbia, Vancouver, British Columbia, Canada

⁶ University of Calgary, Calgary, Alberta, Canada

⁷ University of Toronto, Toronto, Ontario, Canada

⁸ St Michael's Hospital, Toronto, Ontario, Canada

⁹ Spectrum Research, Inc, Tacoma, WA, USA

Corresponding Author:

Paul M. Arnold, MD, University of Kansas School of Medicine, Kansas City, KS 66160, USA.

Email: parnold@kumc.edu



with SCI often require complex spinal surgical procedures to decompress and stabilize their spine and, as a result, are often immobilized for several hours and subjected to further tissue and vessel damage.

VTE is a significant cause of morbidity and mortality in SCI patients and includes both deep vein thrombosis (DVT) and pulmonary embolism (PE).¹ Venous thrombi most commonly form in the lower extremities; here they remain as chronic venous abnormalities, undergo endogenous fibrinolysis and recanalization, or propagate and embolize to the pulmonary system. Obstruction of the pulmonary arteries may lead to a number of life-threatening physiologic changes, including impaired gas exchange, cardiovascular compromise, and right-sided heart failure.

The prevention of DVT and PE is critical in this high-risk population. Prophylactic treatment with anticoagulants and other mechanical strategies may significantly reduce the risk of VTE events in these patients. There may be significant risks to anticoagulant thromboprophylaxis in trauma patients, including symptomatic hematoma formation, enlargement of a spinal cord contusion, worsening of neurologic deficits, bleeding, and mortality.^{3,4}

The objective of this study was to conduct a systematic review to address the following key questions:

In adult patients with acute complete or incomplete traumatic SCI,

Key Question 1: What is the effectiveness and safety of anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another anticoagulant strategy for preventing DVT and PE after acute SCI?

Key Question 2: What is the comparative effectiveness and safety of mechanical prophylaxis strategies alone or in combination with other prophylactic strategies for preventing DVT and PE after acute SCI?

Key Question 3: What is the comparative effectiveness and safety of prophylactic inferior vena cava (IVC) filter insertion alone or in combination with other prophylactic strategies for preventing DVT and PE after acute SCI?

Key Question 4: What is the optimal timing to initiate and/or discontinue anticoagulant, mechanical, and/or prophylactic IVC filter following acute SCI?

Key Question 5: What is the cost-effectiveness of the treatment options mentioned above?

Materials and Methods

Electronic Literature Search

A systematic search of the literature was performed to identify potential studies published through February 28, 2015. Studies in all languages were considered for inclusion. The MEDLINE database was searched using the PubMed interface to identify primary studies and systematic reviews. The Cochrane Collaboration Library and bibliographies of relevant articles were also searched. We focused on studies designed to evaluate the

efficacy/effectiveness and safety of pharmacological, mechanical, and/or prophylactic IVC filter in adults with complete or incomplete acute SCI. Specifically, we sought studies that reported the risks of PE, DVT, bleeding, mortality, and other adverse events following prophylactic treatment. In addition, we searched for studies that examined the optimal timing to initiate and discontinue prophylaxis.

The search strategies are described in the Supplemental Material (available in the online version of the article) and included use of controlled vocabulary (MeSH terms) as well as keywords. For all key questions, terms for anticoagulation were combined with terms specifying SCI. Additional terms for timing were added to the search strategy for Key Question 4 (Supplemental Material). For Key Questions 1, 2, and 3, we focused on randomized controlled trials (RCTs) that evaluated pharmacological and mechanical prophylaxis, and/or prophylactic IVC filters. Since timing of an intervention is a characteristic more likely observed than randomized, we expanded our criteria for Key Question 4 to include all comparative studies. We excluded nonclinical studies, case series, narrative reviews, abstracts/proceedings from meetings, white papers, editorials, and studies with fewer than 10 subjects per treatment arm. The PICO table provides a complete summary of our inclusion/exclusion criteria (Table 1).

Study Selection and Data Abstraction

Studies were included if they examined either (1) the efficacy and/or safety of anticoagulation prophylaxis or (2) the optimal timing to initiate and/or discontinue prophylaxis in patients with acute SCI. Two reviewers (JH and HH) independently identified potential studies from the literature search. In instances of disagreement regarding inclusion, a third reviewer (DN) was consulted and consensus achieved through discussion. If an article published in a foreign language appeared to meet inclusion criteria based on the English abstract, we used Google Translate⁵ to translate the entire article into English. If any part of the translation was unclear, we sought human translation assistance.

One reviewer (JH) used standardized forms to extract the following data: age, sex, completeness and level of SCI, dose and frequency of antithrombotic drugs, intervention characteristics for mechanical and/or invasive prophylaxis, timing and duration of prophylaxis, methods used to diagnose DVT and PE, and results. A second reviewer checked the abstractions for accuracy and completeness (HH).

Individual Study Quality

Two independent reviewers (HH and DN) critically appraised each included study for risk of bias using criteria outlined by *The Journal of Bone & Joint Surgery, American Volume*⁶ for therapeutic studies and modified to encompass criteria associated with methodological quality⁷ (see the Supplemental Material for individual study ratings; available in the online version of the article). Disagreements in ratings were resolved through discussion.

Table 1. Inclusion and Exclusion Criteria.

Study Component	Inclusion	Exclusion
Population	Adults with traumatic acute spinal cord injury (complete or incomplete, at any level)	<ul style="list-style-type: none"> • Pediatric patients • Pregnancy • Penetrating injuries to spinal cord • Cord compression due to tumor, hematoma, or degenerative disease (eg, CSM) • Patients without neurological deficit following trauma
Intervention	KQ1: Any antithrombotic drug strategy KQ2: Any mechanical strategy (intermittent pneumatic compression devices, stockings, etc) used alone KQ3: Prophylactic IVC filters used alone KQ4: Any antithrombotic drug, mechanical, and/or prophylactic IVC filter strategy initiated and/or discontinued at a specific timing KQ5: Any interventions included in KQs 1-4	
Comparators	KQ1: Any other antithrombotic drug, placebo, or no prophylactic intervention KQ2: Any mechanical strategy (intermittent pneumatic compression devices, stockings, etc) used alone or in combination with other prophylactic strategies KQ3: Prophylactic IVC filters used in combination with other prophylactic strategies KQ4: Same anticoagulant, mechanical (intermittent pneumatic compression devices, stockings, etc), and/or prophylactic IVC filters initiated and/or discontinued at another timing KQ5: Any comparators included in KQs 1-4	
Outcomes	<i>Efficacy/effectiveness</i> <ul style="list-style-type: none"> • Rate of deep venous thrombosis • Rate of pulmonary embolism <i>Safety</i> <ul style="list-style-type: none"> • Bleeding • Mortality • Other adverse events <i>Cost-effectiveness</i> <ul style="list-style-type: none"> • Incremental cost-effectiveness ratio (or similar) • Cost per unit of outcome 	
Study design	KQs 1-3: Randomized controlled trials KQ4: Randomized controlled trials and comparative non-randomized studies KQ5: Full economic studies	<ul style="list-style-type: none"> • Animal studies • Nonclinical studies • Case series • n < 10 per treatment arm • Abstracts, editorials, letters • Duplicate publications of the same study which do not report on different outcomes • Single-center reports from multicenter trials • White papers • Narrative reviews • Proceedings/abstracts from meetings • Articles identified as preliminary reports if results are published in later versions
Publication	<ul style="list-style-type: none"> • Studies with abstracts • Published or translated into English in peer-reviewed journals 	

Abbreviations: CSM, cervical spondylotic myelopathy; IVC, inferior vena cava; KQ, key question.

Overall Strength of Body of Literature

After rating each individual article, the strength of the overall body of evidence with respect to each outcome was determined based on precepts outlined by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group^{8,9} and recommendations made by

the Agency for Healthcare Research and Quality (AHRQ).^{10,11} Additional qualitative analysis was performed according to AHRQ-required (risk of bias, consistency, directness, precision) and additional domains (dose-response, strength of association, publication bias).¹² In general, risk of bias was determined when evaluating each individual article as described above.

The initial strength of the overall body of evidence was considered “High” for RCTs and “Low” for observational studies. The body of evidence could be downgraded 1 or 2 levels based on the following criteria: (1) risk of bias (study limitations), (2) inconsistency of results, (3) indirectness of evidence, (4) imprecision of the effect estimates (eg, wide confidence intervals), or (4) failure to provide an a priori statement of subgroup analyses. The body of evidence could be upgraded 1 or 2 levels based on the following criteria: (1) large magnitude of effect or (2) dose-response gradient or (3) if all plausible biases would decrease the magnitude of an apparent effect.

The final overall strength of the body of literature expresses (1) our confidence that the effect size lies close to the true effect and (2) the extent to which the effect is believed to be stable based on the adequacy of or deficiencies in the body of evidence.⁹ An overall strength of “High” means that we are very confident that the true effect lies close to that of the estimated effect. A “Moderate” rating means that we are moderately confident in the effect estimate; the true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. An overall strength of “Low” means that our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate. Finally, a rating of “Insufficient” means that we have very little confidence in the effect estimate; the true effect is likely to be substantially different than the estimated effect. In addition, this rating may be used if there is no evidence or it is not possible to estimate an effect.

Analysis

When data was available, we calculated risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (95% CIs) to provide an estimate of effect size. Fisher exact test was used to calculate *P* values due to the low number of events. *P* values <.05 were considered statistically significant. Calculations were performed using Stata 9.0.¹³ Pooling of data was performed if studies were reasonably homogeneous with respect to patient population, study quality, interventions, and outcome measures.

Results

The search yielded 282 citations. Four additional primary studies were identified from the bibliographies of other published articles. Two hundred and sixty-nine citations were excluded based on their title and/or abstract, while 17 were selected for full-text investigation (Figure 1). A total of 8 RCTs¹⁴⁻²¹ met inclusion criteria for Key Questions 1, 2, and 3 and are summarized in this review. Additionally, we identified one prospective, nonrandomized comparative study²² that satisfied the inclusion criteria for Key Question 4. Study characteristics, patient demographics, and detailed results are provided in the abstraction tables located in the Supplemental Material (available in the online version of the article).

Our intent was to combine data into a meta-analysis where possible; however, all comparisons either did not have 2 or more




Figure 1. Study selection flow chart.

studies, or the studies were too heterogeneous with regard to populations, interventions, and/or outcomes to enable pooling.

Key Question 1. What Is the Effectiveness and Safety of Anticoagulant Thromboprophylaxis Compared to No Prophylaxis, Placebo, or Another Anticoagulant Strategy for Preventing DVT and PE After Acute SCI?

Seven RCTs^{14-17,19,21,23} reported on the efficacy and/or safety of anticoagulant drug interventions. Two additional studies claimed randomization but were excluded for the following reasons: (1) one study²⁴ did not re-randomize patients following the acute phase of the trial but rather selected their subjects based on whether or not they successfully completed the acute treatment phase; and (2) a second study²⁵ included patients that were assigned alternately (ie, not randomly) to treatment groups. The 7 included studies were stratified as follows: (1) low-molecular-weight heparin (LMWH; enoxaparin) versus no prophylaxis²³; (2) LMWH (enoxaparin) versus LMWH (dalteparin)¹⁵; (3) fixed-dose versus adjusted-dose unfractionated heparin (UFH)¹⁶; (4) LMWH (tinzaparin and dalteparin) versus UFH^{17,21}; and (5) UFH versus no treatment or placebo.^{14,19}

LMWH Versus No Prophylaxis. A single RCT compared the efficacy of LMWH versus no anticoagulant prophylaxis. This trial²³ reported the risks of DVT and PE in groups that received either enoxaparin (40 mg subcutaneously one time per day for 8 weeks) or no prophylaxis (both groups had compression stockings). Patients treated with enoxaparin had a lower rate of DVT (5.4%) than those who received no LMWH prophylaxis (21.6%; RD = 16.2, 95% CI = 1.1 to 31.4; RR = 4.0, 95% CI = 0.91 to 17.6; *P* = .09). The authors reported a statistically

Table 2. Risks of DVT and PE in Patients With Traumatic Spinal Cord Injury Who Received Enoxaparin Versus No Prophylaxis.

	No Prophylaxis, % Patients (n/N)	Enoxaparin, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Halim (2014) (N = 74)	21.6% (8/37)	5.4% (2/37)	4.0 (0.91 to 17.6)	16.2 (1.1 to 31.4)	P = .09

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; PE, pulmonary embolism; RD, risk difference; RR, risk ratio.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

Table 3. Risks of DVT in Patients With Traumatic Spinal Cord Injury Who Received UFH Versus Placebo/No Prophylaxis.

	UFH, % Patients (n/N)	Placebo, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Agarwal (2009) (N = 297)	1.8% (3/166)	3% (4/131)	0.59 (0.13 to 2.6)	1.2 (-2.3 to 4.8)	P = .70
Merli (1988) (N = 33)	50% (8/16)	47% (8/17)	1.06 (0.53 to 2.15)	2.9 (-31.2 to 37.0)	P = 1.0

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; RD, risk difference; RR, risk ratio; UFH, unfractionated heparin.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

Table 4. Risks of DVT, PE, Bleeding, and Mortality in Patients With Traumatic Spinal Cord Injury Who Received Enoxaparin Versus Dalteparin.

	Enoxaparin, % Patients (n/N)	Dalteparin, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Chiou-Tan (2003) (N = 95)	6% (3/50)	4% (2/45)	1.35 (0.24 to 7.72)	1.6 (-7.3 to 10.5)	P = 1.0
<i>Risk of PE</i>					
Chiou-Tan (2003) (N = 95)	0% (0/50)	0% (0/45)	NC	0	P = 1.0
<i>Risk of bleeding</i>					
Chiou-Tan (2003) (N = 95)	2% (1/50)	4% (2/45)	0.45 (0.04 to 4.8)	2.4 (-9.6 to 4.7)	P = .60
<i>Mortality</i>					
Chiou-Tan (2003) (N = 95)	0% (0/50)	0% (0/45)	NC	0	P = 1.0

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk difference; RR, risk ratio.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

significant difference ($P = .04$); however, we reanalyzed this data due to the low number of events using the more conservative Fisher exact test and found no significant difference. Risk of PE, bleeding, and mortality were not reported (Table 2).

UFH Versus Placebo or No Treatment. Two RCTs assessed the risk of DVT in patients receiving UFH (5000 U subcutaneously every 12 hours¹⁴ or every 8 hours¹⁹) versus no treatment or placebo.^{14,19} The rates of DVT did not significantly differ between the UFH and the placebo/no prophylaxis groups (1.8% and 3%, respectively, in one trial¹⁴ and 50% and 47%, respectively, in the other trial¹⁹; Table 3).

LMWH Versus LMWH. A single RCT compared the efficacy and safety of 2 different LMWH drugs. This trial¹⁵ reported on the risks of DVT, PE, bleeding, and mortality in groups that received either enoxaparin (30 mg subcutaneously every 12 hours) or dalteparin (5000 IU subcutaneously once daily). There was no statistically significant difference in the rate of DVT between the

enoxaparin and dalteparin groups (6% and 4%, respectively; RD = 1.6, 95% CI = -7.3 to 10.5; RR = 1.35, 95% CI = 0.24 to 7.72; $P = 1.0$). Furthermore, no patients in either group suffered a PE. Both treatments were also equally safe: (1) only 1 patient in the enoxaparin group and 2 patients in the dalteparin group experienced a bleeding event (RD = 2.4, 95% CI = -9.6 to 4.7; RR = 0.45, 95% CI = 0.04 to 4.8; $P = .6$); and (2) no patients died in either group (Table 4).

Fixed, Low-Dose UFH Versus Adjusted-Dose UFH. One RCT evaluated the efficacy and safety of fixed, low-dose versus adjusted-dose UFH. This trial¹⁶ discussed the risks of DVT, PE, and bleeding in groups that received either a fixed, low-dose (initial dose of 5000 U and then 5000 U given subcutaneously every 12 hours) or adjusted-dose (initial dose of 5000 U and then adjusted as necessary to keep the activated partial thromboplastin time value in the 40-50 seconds range) of UFH. VTE (DVT and/or PE) was seen in 9/29 (31.0%) and 2/29

Table 5. Risks of DVT, PE, and Bleeding in Patients With Traumatic Spinal Cord Injury Who Received Fixed, Low-Dose Heparin Versus Adjusted-Dose Heparin.

	Fixed, Low-Dose Heparin, % Patients (n/N)	Adjusted-Dose Heparin, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Green (1988) (N = 58)	20.7% (6/29)	6.9% (2/29)	3.0 (0.66 to 13.7)	13.8 (−3.6 to 31.2)	P = .25
<i>Risk of PE</i>					
Green (1988) (N = 58)	10.3% (3/29)	0% (0/29)	NC	10.3 (−0.7 to 21.4)	P = .24
<i>Risk of bleeding</i>					
Green (1988) (N = 58)	0% (0/29)	24.1% (7/29)	NC	24.1 (8.6 to 39.7)	P = .01

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk difference; RR, risk ratio.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

Table 6. Risks of DVT, PE, Bleeding, and Mortality in Patients With Traumatic Spinal Cord Injury Who Received LMWH Versus UFH.

	LMWH, % Patients (n/N)	UFH, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Green (1990) (N = 41)	0% (0/20)	14.3% (3/21)	NC	14.3 (−0.7 to 29.3)	P = .23
Lohmann (2001) (N = 166)	7.5% (6/80)	14% (12/86)	0.54 (0.21 to 1.4)	6.5 (−2.9 to 15.8)	P = .18
<i>Risk of PE</i>					
Green (1990) (N = 41)	0% (0/20)	9.5% (2/21)	NC	9.5 (−3.0 to 22.1)	P = .49
Lohmann (2001) (N = 166)	1.25% (1/80)	2.3% (2/86)	0.54 (0.05 to 5.8)	1.1 (−2.9 to 0.05)	P = .60
<i>Risk of bleeding</i>					
Green (1990) (N = 41)	0% (0/20)	9.5% (2/21)	NC	9.5 (−3.0 to 22.1)	P = .49
<i>Mortality</i>					
Green (1990) (N = 41)	0% (0/20)	9.5% (2/21)	NC	9.5 (−3.0 to 22.1)	P = .49

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk difference; RR, risk ratio; UFH, unfractionated heparin.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

(6.9%), respectively ($P = .04$). The risk of DVT in the fixed, low-dose group was 3 times greater than the adjusted-dose group (RD = 13.8, 95% CI = −3.6 to 31.2; RR = 3.0, 95% CI = 0.66 to 13.7; $P = .25$; Table 5). Three patients (10.3%) in the fixed, low-dose group experienced a PE, whereas no patients in the adjusted group suffered this complication; this difference did not reach statistical significance (RD = 10.3, 95% CI = −0.7 to 21.4; $P = .24$). The rate of bleeding was significantly higher in patients treated with adjusted-dose heparin (24.1%) than those receiving low-dose (0%; RD = 24.1, 95% CI = 8.6 to 39.7; $P = .01$; Table 5).

LMWH Versus UFH. Two RCTs examined the relative efficacy and safety of LMWH versus UFH. One trial¹⁷ reported on the risks of DVT, PE, bleeding, and mortality in patients that received either LMWH (tinzaparin 3500 anti-Xa units given subcutaneously once daily) or UFH (fixed doses of 5000 U given subcutaneously every 8 hours). No patients in the LMWH group experienced a DVT or PE, whereas in the UFH group, 3 (14%) patients suffered a DVT and 2 (9.5%) a PE; these differences were not statistically significant for either outcome due to the low number of events (Table 6). There was a higher rate of bleeding (9.5%) and mortality (9.5%) in the UFH group

compared to the LMWH group (0% and 0%, respectively), although these relationships did not reach statistical significance.

A second trial²¹ also discussed the risks of DVT and PE events in patients who received either LMWH (dalteparin; 5000 anti-Xa units given subcutaneously once daily) or UFH (7500 U given subcutaneously twice daily). Similarly, the risks of DVT (7.5% and 14% for LMWH and UFH, respectively) and PE (1.25% and 2.3% for LMWH and UFH, respectively) were lower in the LMWH group than in the UFH group; however, these differences did not reach statistical significance (DVT: RD = 6.5, 95% CI = −2.9 to 15.8; RR = 0.54, 95% CI = 0.21 to 1.4; $P = .18$; PE: RD = 1.1, 95% CI = −2.9 to 0.05; RR = 0.54, 95% CI = 0.05 to 5.8; $P = .60$). In this analysis, we did not pool the data from these 2 studies due to differences between dalteparin and tinzaparin (Table 6).

Key Question 2. What Is the Comparative Effectiveness and Safety of Mechanical Strategies Alone or in Combination With Other Prophylactic Strategies for Preventing DVT and PE After Acute SCI?

Three RCTs¹⁸⁻²⁰ reported on the efficacy and/or safety of mechanical strategies alone or in combination with

Table 7. Risks of DVT and Bleeding in Patients With Traumatic Spinal Cord Injury Who Received Mechanical Prophylaxis Alone Versus Mechanical Plus Anticoagulant Prophylaxis.

	IPC, % Patients (n/N)	IPC + Aspirin + Dipyridamole, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Green (1982) (N = 27)	40% (6/15)	25% (3/12)	1.6 (0.50 to 5.10)	15.0 (−19.9 to 49.9)	P = .68
<i>Risk of bleeding</i>					
Green (1982) (N = 27)	0% (0/15)	8.3% (1/12)	NC	8.3 (−7.3 to 24.0)	P = .44

Abbreviations: CI, confidence interval; IPC, intermittent pneumatic compression; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; RD, risk difference; RR, risk ratio.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

antithrombotic drug interventions. The 3 included studies compared the following prophylactic treatments: (1) mechanical versus mechanical + antithrombotic drugs¹⁸ and (2) anticoagulant versus anticoagulant + mechanical.^{19,20}

Mechanical Versus Mechanical + Antithrombotic Drugs. A single RCT compared the efficacy and safety of mechanical prophylaxis versus mechanical prophylaxis plus antithrombotic drugs.¹⁸ This study reported on the risks of DVT and bleeding in 28 patients who received intermittent pneumatic compression (IPC) alone and those who were treated with IPC plus aspirin and dipyridamole (IPC plus aspirin 300 mg BID and dipyridamole 75 mg TID). A higher percentage of patients experienced a DVT in the IPC-only group (40%) than in the IPC plus aspirin and dipyridamole group (25%); however, this difference was not statistically significant (RD = 15.0, 95% CI = −19.9 to 49.9; RR = 1.6, 95% CI = 0.50 to 5.10; *P* = .68). There was also no difference in safety between treatment groups: no patients in the IPC group and only one patient in the IPC plus aspirin and dipyridamole group reported an adverse bleeding event (RD = 8.3, 95% CI = −7.3 to 24.0; *P* = .44; Table 7).

Anticoagulant Versus Anticoagulant + Mechanical. Two RCTs compared outcomes between anticoagulant thromboprophylaxis and anticoagulant plus mechanical prophylaxis.^{19,20} The first trial¹⁹ investigated the use of UFH alone (5000 U subcutaneously every 8 hours) versus UFH plus electric stimulation (UFH as described above, plus tibialis anterior and gastrocnemius-soleus stimulated bilaterally for 23 hours per day), and a second trial²⁰ compared the use of LMWH (enoxaparin; 30 mg subcutaneously every 12 hours) versus UFH (5000 U subcutaneously every 8 hours) plus IPC (used at least 22 hours each day). The first trial¹⁹ only discussed the risk of DVT, whereas the other²⁰ reported on rates of DVT, PE, all VTE, major and minor bleeding, and mortality. Both studies reported higher risks of DVT in the group that received anticoagulant prophylaxis only (50% and 60.3%, respectively) than in the group that received combined anticoagulant and mechanical intervention (6.7% and 44.9%, respectively; Table 8). In the trial that compared UFH alone versus UFH plus electric stimulation,¹⁹ the increased risk of DVT in the anticoagulant

prophylaxis group (50%) was nearly 8 times that of the combined treatment group (6.7%; RD = 43.3, 95% CI = 15.8 to 70.9; RR = 7.5, 95% CI = 1.06 to 53.03; *P* = .02). In the second trial,²⁰ 60.3% of patients treated with LMWH experienced a DVT, whereas only 44.9% of patients who received UFH plus IPC suffered this adverse event (RD = 15.4, 95% CI = −3.3 to 34.2; RR = 1.34, 95% CI = 0.92 to 1.95; *P* = .12; Table 8). The data was not pooled across studies due to differences in the anticoagulant and mechanical prophylaxis used in these trials.

In the Spinal Cord Injury Thromboprophylaxis Investigators (SCITI) trial,²⁰ patients in the LMWH-only group experienced fewer PE events compared to patients in the UFH plus IPC group (5.2% and 18.4%, respectively); this difference was nearly statistically significant (RD = 13.2, 95% CI = 0.9 to 25.4; RR = 0.28, 95% CI = 0.08 to 0.98; *P* = .06). The risk of all VTE, major and minor bleeding, and mortality were similar between groups (Table 8).

Key Question 3. What Is the Comparative Effectiveness and Safety of Prophylactic IVC Filter Insertion Alone or in Combination With Other Prophylactic Strategies for Preventing DVT and PE After Acute SCI?

We did not identify any RCTs that met our inclusion criteria for this key question.

Key Question 4. What Is the Optimal Timing to Initiate and/or Discontinue Anticoagulant, Mechanical, and/or Prophylactic IVC Filter Following Acute SCI?

One prospective, non-RCT²² examined the timing of initiation of anticoagulant thromboprophylaxis in patients with acute SCI. This study reported on the risks of DVT and PE in patients that received prophylaxis initiated within (early group) or after (late group) 72 hours of injury. The prophylactic protocol consisted of LMWH (nadroparin; 0.4 mL once per day) plus early mobilization, graduated compression stockings (GCS), and IPC devices (3 hours per day given in 2 applications) for the lower limbs. The number of patients who suffered a DVT was significantly lower in the early group (*n* = 2) compared to the late

Table 8. Risks of DVT, PE, All VTE, Major Bleeding, Minor Bleeding, and Mortality in Patients With Traumatic Spinal Cord Injury Who Received Anticoagulant Prophylaxis Alone Versus Anticoagulant Plus Mechanical Prophylaxis.

	Anticoagulant, % Patients (n/N)	Anticoagulant + Mechanical, % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Merli (1988) (N = 31)	50% (8/16)	6.7% (1/15)	7.5 (1.06 to 53.03)	43.3 (15.8 to 70.9)	P = .02
SCITI ^c (2003) (N = 107)	60.3% (35/58)	44.9% (22/49)	1.34 (0.92 to 1.95)	15.4 (-3.3 to 34.2)	P = .12
<i>Risk of PE</i>					
SCITI ^c (2003) (N = 107)	5.2% (3/58)	18.4% (9/49)	0.28 (0.08 to 0.98)	13.2 (0.9 to 25.4)	P = .06
<i>Risk of all VTE</i>					
SCITI ^c (2003) (N = 107)	65.5% (38/58)	63.3% (31/49)	1.04 (0.78 to 1.38)	2.3 (-16.0 to 20.5)	P = .84
<i>Risk of major bleeding</i>					
SCITI (2003) (N = 476)	2.6% (6/230)	5.3% (13/246)	0.49 (0.19 to 1.28)	2.7 (-0.8 to 6.1)	P = .16
<i>Risk of minor bleeding</i>					
SCITI (2003) (N = 476)	14.8% (34/230)	17.9% (44/246)	0.83 (0.55 to 1.25)	3.1 (-3.5 to 9.7)	P = .39
<i>Mortality</i>					
SCITI (2003) (N = 476)	0.9% (2/230)	0.8% (2/246)	1.07 (0.15 to 7.53)	0.1 (-1.5 to 2.5)	P = 1.0

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; PE, pulmonary embolism; RD, risk difference; RR, risk ratio; VTE, venous thromboembolism.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

^cPatients with adequate proximal and distal diagnostic imaging or evidence of PE.

Table 9. Risks of DVT and PE in Patients With Traumatic Spinal Cord Injury Who Received Early (≤72 Hours) Versus Late (>72 Hours) Prophylaxis.

	Early (≤72 Hours), % Patients (n/N)	Late (>72 Hours), % Patients (n/N)	RR (95% CI) ^a	RD (95% CI) ^a	P Value ^b
<i>Risk of DVT</i>					
Aito (2002) (N = 275)	2% (2/99)	26% (46/176)	12.9 (3.2 to 51.2)	24.1 (17.1 to 31.2)	P < .001
<i>Risk of PE</i>					
Aito (2002) (N = 275)	0% (0/99)	0% (0/176)	NC	0	P = 1.0

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk difference; RR, risk ratio.

^aCalculated from data provided by authors of primary studies.

^bP value calculated using Fisher exact test.

group (n = 46; RD = 24.1, 95% CI = 17.1 to 31.2; RR = 12.9, 95% CI = 3.2 to 51.2; P < .001; Table 9). No patients in either group experienced a PE event. Safety outcomes were not reported in this study.

Key Question 5. What Is the Cost-Effectiveness of the Treatment Options Evaluated in Key Questions 1 to 4?

We did not identify any studies that met our inclusion criteria for this Key Question.

Strength of Evidence Summary

See the Supplemental Material for detailed tables (available in the online version of the article).

Key Question 1. What is the effectiveness and safety of anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another anticoagulant strategy for preventing DVT and PE after acute SCI?

Overall, the strength of evidence was low for evaluating the comparative efficacy and safety of various anticoagulant prophylactic strategies (eg, enoxaparin, dalteparin, tinzaparin, UFH) in patients with acute SCI. The strength of evidence was moderate for comparing the efficacy and safety of fixed, low-dose versus adjusted-dose UFH.

LMWH versus no prophylaxis. There is low-quality evidence that the risk of DVT (but not PE) is higher in patients who received no prophylaxis compared to those who received LMWH (enoxaparin). The risk of DVT was 4 times greater in patients treated without prophylaxis; however, this did not quite reach statistical significance in our conservative analysis (Table 10).

UFH versus placebo or no treatment. There is low-quality evidence that there is no difference in the risk of DVT in patients treated with either UFH or placebo/no prophylaxis (Table 10).

Table 10. Summary GRADE Table for Key Question 1: What Is the Effectiveness and Safety of Anticoagulant Thromboprophylaxis Compared to No Prophylaxis, Placebo, or Another Anticoagulant Strategy for Preventing DVT and PE After Acute Spinal Cord Injury?

Comparisons	Number of Studies (N)	Strength of Evidence Grade	Conclusions, Effect Size
Enoxaparin vs No prophylaxis	1 RCT (N = 74) (Halim, 2014)	Low	Based on a single RCT, patients treated with enoxaparin had a lower rate of DVT (5.4%) than those who received no anticoagulant prophylaxis (21.6%), although this relationship did not reach statistical significance using the conservative Fisher exact test. There were no observed PE events in either group. Bleeding and mortality were not reported.
UFH vs No treatment or Placebo	1 RCT (N = 297) (Agarwal, 2009) 1 RCT (N = 33) (Merli, 1988)	Low	Based on 2 RCTs, rates of DVT did not significantly differ between the UFH and the placebo/no prophylaxis group (1.8% and 3% in one trial and 50% and 47% in the other trial).
Enoxaparin vs Dalteparin	1 RCT (N = 95) (Chiou-Tan, 2003)	Low	Based on a single small RCT, there were no statistically significant differences in the rate of DVT between the enoxaparin and dalteparin groups. No patients in either group suffered a PE. There were also no differences between the groups with respect to safety.
Fixed, low-dose vs Adjusted-dose heparin	1 RCT (N = 58) (Green, 1988)	Low	The risks of DVT and PE were greater in the fixed, low-dose group (20.7% and 6.9%, respectively) than in the adjusted-dose group (10% and 0%, respectively). These relationships were not statistically significant due to low event rates.
		Moderate	The rate of bleeding was significantly higher in patients treated with adjusted-dose heparin (24.1%) than those receiving low-dose heparin (0%).
LMWH vs UFH	1 RCT (N = 41) (Green, 1990) 1 RCT (N = 166) (Lohmann, 2001)	Low	Based on 2 RCTs, there were no significant differences in risk of DVT, PE, bleeding or mortality between patients treated with LMWH versus UFH. The number of events were very small in both groups.
Tinzaparin vs UFH			
Dalteparin vs UFH			

Abbreviations: DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized controlled trial; UFH, unfractionated heparin.

LMWH versus LMWH. There is low-quality evidence that there is no difference in the risks of DVT, PE, bleeding, or mortality between patients administered with enoxaparin and those treated with dalteparin (Table 10).

LMWH versus UFH. There is low-quality evidence that there is no difference in the risks of DVT, PE, bleeding, or mortality in patients who received either LMWH (tinzaparin or dalteparin) or UFH (Table 10).

Fixed, low-dose UFH versus adjusted-dose UFH. There is low-quality evidence that the risk of DVT (but not PE) is higher in patients who received fixed, low-dose heparin compared to those treated with adjusted-dose heparin. There is moderate quality evidence that patients administered with fixed, low-dose heparin have a lower risk of bleeding than those who received an adjusted-dose (Table 10).

Key Question 2. What is the comparative effectiveness and safety of mechanical strategies alone or in combination with other prophylactic strategies for preventing DVT and PE after acute SCI? Overall, the strength of evidence was low for evaluating the comparative efficacy and safety of mechanical prophylactic

strategies (eg, IPC, electric calf stimulation) alone or in combination with other prophylactic strategies (eg, UFH, aspirin).

Mechanical versus mechanical + anticoagulant. There is low-quality evidence to suggest that there is no difference in the risk of DVT or bleeding between patients receiving IPC alone versus IPC plus aspirin and dipyridamole (Table 11).

Anticoagulant versus anticoagulant + mechanical. There is low-quality evidence that patients who received a combination of UFH and electric calf stimulation have a lower risk of DVT than patients treated with UFH alone. There is low-quality evidence that there is no difference in the risk of DVT in patients who received LMWH alone compared to those treated with UFH plus IPC. There is low-quality evidence that patients administered with LMWH alone have a lower risk of PE compared with patients who received UFH plus IPC. Based on low-quality evidence, there is also no difference in the risks of VTE, major and minor bleeding, and mortality between patients who received LMWH and those treated with UFH plus IPC (Table 11).

Key Question 3: What is the comparative effectiveness and safety of prophylactic IVC filter alone or in combination with other

Table 11. Summary GRADE Table for Key Question 2: What Is the Comparative Effectiveness and Safety of Mechanical Strategies Alone or in Combination With Other Prophylactic Strategies for Preventing DVT and PE After Acute Spinal Cord Injury?

Comparisons	Number of Studies (N)	Strength of Evidence Grade	Conclusions, Effect Size
Mechanical vs Mechanical + Anticoagulant IPC only vs IPC + Aspirin + Dipyridamole	1 RCT (N = 27) (Green, 1982)	Low	A higher percentage of patients experienced a DVT in the IPC only group (40%) than in the IPC plus aspirin and dipyridamole group (25%); however, this difference was not statistically significant. There was also no difference in rates of bleeding between groups.
Mechanical + Anticoagulant vs anticoagulant UFH + Electric calf stimulation vs UFH	1 RCT (N = 31) (Merli, 1988)	Low	Based on a single RCT, the increased risk of DVT in the anticoagulant prophylaxis group (50%) was nearly 8 times that of the combined treatment group (6.7%).
UFH + IPC vs LMWH	1 RCT (N = 107) (SCITI, 2003)		In a second RCT, 60.3% of patients treated with LMWH experienced a DVT, whereas 44.9% of patients who received UFH plus IPC suffered this complication (not statistically significant). The risk of PE was higher in the UFH + IPC group (18.4%) compared to the LMWH group (5.2%). The risks of all VTE, major and minor bleeding, and mortality were similar between groups.

Abbreviations: DVT, deep vein thrombosis; IPC, intermittent pneumatic compression; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized controlled trial; UFH, unfractionated heparin; VTE, venous thromboembolic event.

prophylactic strategies for preventing DVT and PE after acute SCI?
We did not identify any studies that met our inclusion criteria. There is therefore insufficient evidence to answer this key question.

Key Question 4. *What is the optimal timing to initiate and/or discontinue anticoagulant, mechanical and/or prophylactic IVC filter following acute SCI?*

There is low-quality evidence that the risk of DVT is significantly lower in patients receiving prophylaxis within 72 hours than those treated after 72 hours of injury. The prophylactic treatment protocol in this study was LMWH plus early mobilization, GCS, and IPC of the lower limbs. The level of evidence was upgraded from insufficient due to the strong magnitude of effect. There is no difference between these groups regarding the risk of PE; however, the evidence for this conclusion is insufficient (Table 12).

Key Question 5. *What is the cost-effectiveness of the treatment options evaluated in Key Questions 1 to 4?*

We did not identify any studies that met our inclusion criteria. There is therefore insufficient evidence to answer this key question.

Discussion

SCI is associated with an increased risk of VTE due to neurologic dysfunction, immobilization, and hypercoagulability.¹ These patients experience extensive tissue damage and are commonly treated with invasive surgical procedures. As a result, there is a fear of hemorrhage or bleeding, particularly around neural tissues where a minor hematoma can have devastating consequences such as paralysis. Surgeons must implement appropriate anticoagulation strategies to reduce the risk of DVT and PE without increasing the risk of hemorrhagic

Table 12. Summary GRADE Table for Key Question 4: What Is the Optimal Timing to Initiate and/or Discontinue Anticoagulant, Mechanical, and/or Prophylactic IVC Filter Following Acute Spinal Cord Injury?

Comparisons	Number of Studies (N)	Strength of Evidence Grade	Conclusions, Effect Size
≤72 hours vs >72 hours: LMWH + Early mobilization + Compression stockings + IPC	1 RCT (N = 275) (Aito, 2002)	Low	The number of patients who suffered a DVT was significantly lower in the early intervention group (n = 2) compared to the late group (n = 46). Insufficient ^a No PE events were observed.

Abbreviations: DVT, deep vein thrombosis; IPC, intermittent pneumatic compression; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized controlled trial.

^aConclusions are not possible due to study limitations (ie, methodology), small sample sizes resulting in low precision of estimates, and/or limited data from single studies.

complications. This review compared the efficacy and safety of various prophylactic treatment protocols, including antithrombotic drugs, mechanical strategies, and prophylactic IVC filter.

Antithrombotic Drug Strategies

Antithrombotic drugs for DVT and PE prophylaxis target the coagulation cascade. Halim et al reported that patients who did not receive any active thromboprophylaxis were at 4 times higher risk of DVT than those treated with LMWH (enoxaparin).²³ In

their study, this relative risk was reported as statistically significant. In our systematic review, however, we reanalyzed their data using the conservative Fisher exact test due to the low number of events; the comparison between groups approached but did not reach statistical significance. Thus, although this conclusion agrees with clinical observations that anticoagulant thromboprophylaxis is superior to no treatment for preventing DVT, more definitive evidence is required.

In this review, several studies evaluated the relative efficacy and safety of various anticoagulant strategies, including enoxaparin versus dalteparin,¹⁵ fixed- versus adjusted-dose UFH,¹⁶ and UFH versus LMWH.^{17,21} There was no statistically significant difference in the efficacy or safety between 2 types of LMWH, enoxaparin (30 mg subcutaneously every 12 hours) or dalteparin (5000 IU subcutaneously once daily); however, only 95 patients were evaluated.

In a study by Green et al, the risk of DVT in patients treated with fixed, low-dose UFH was nearly 3 times greater than in patients receiving an adjusted dose.¹⁶ Although this conclusion might suggest that adjusted-dose UFH is a superior therapy, this relationship did not reach statistical significance and the rate of adverse bleeding events was significantly higher than in the fixed, low-dose group. Given that patients with SCI are often managed surgically, anticoagulant doses that cause excessive bleeding should be avoided.

There was a tendency for reduced risk of DVT and PE in patients receiving LMWH compared to those treated with UFH.¹⁷ Low event rates in both groups, however, prevented definitive conclusions from being made. Furthermore, there were no statistically significant differences in rates of bleeding or mortality between prophylactic treatment groups. Other factors may also be considered when devising an appropriate treatment protocol, including cost and heparin-induced thrombocytopenia. LMWH is typically a more expensive therapy than UFH treatment. Patients treated with UFH, however, also have a much higher incidence of heparin-induced thrombocytopenia (2.6%) compared to users of LMWH (0.2%).²⁶

Combined Strategies

Green et al compared the risks of DVT and bleeding in patients who received mechanical prophylaxis alone or in combination with an antiplatelet strategy.¹⁸ Based on their results, there was a higher rate of DVT in the IPC-only group (40%) than in the IPC plus aspirin and dipyridamole group (25%); however, this difference was not statistically significant. Mechanical prophylaxis, in combination with antithrombotic drug strategies, may work synergistically to reduce the risk of DVT. There was no significant difference in risk of bleeding between treatment groups.

Two other studies evaluated the relative efficacy and safety of anticoagulant thromboprophylaxis versus combined anticoagulant and mechanical strategies.^{19,20} Merli et al reported a significantly reduced risk of DVT in patients who received UFH plus electric calf stimulation compared to those treated with only UFH.¹⁹ This result indicates that DVT may be best prevented through combined strategies that reduce stasis as

well as hypercoagulability. Furthermore, electric calf stimulation may decrease stasis better than IPC as it compresses the calf muscle at a greater frequency.¹⁹

The SCITI trial compared the risk of DVT, PE, major and minor bleeding, and mortality between patients treated with LMWH and those who received a combination of UFH and IPC.²⁰ Rates of all VTE were similar between groups, 63% versus 66%, respectively. There was a trend toward a lower rate of DVT in the UFH plus IPC group (44.9%) compared with the LMWH group (60.3%), while the rate of PE was higher in the combined anticoagulant and mechanical prophylaxis group. The risk of major and minor bleeding and mortality did not differ between treatment groups.

Prophylactic IVC Filter Strategies

No studies evaluated the efficacy and safety of prophylactic IVC filters in patients with traumatic SCI. In a study by McClendon et al, the use of prophylactic IVC filters reduced the odds of developing a PE in patients undergoing major spinal reconstructive surgery compared to population controls.²⁷ Furthermore, Rodriguez et al reported a significantly decreased incidence of PE in patients at a high risk of this complication.²⁸ However, in a retrospective study of 54 SCI patients, the insertion of a prophylactic IVC filter increased the risk of DVT compared to a control group despite the routine use of anticoagulant thromboprophylaxis.²⁹ Further research is needed to confirm the efficacy and safety of prophylactic IVC filters in patients with SCI.

Timing of Prophylaxis

Spine surgeons must determine the ideal timing to initiate anticoagulant thromboprophylaxis in patients with either isolated SCI or with other additional traumatic injuries. These decisions must balance the need to prevent DVT and PE with the risk of increased bleeding. In a study by Aito et al, the risk of DVT was 13 times greater if prophylaxis (anticoagulant with mechanical) was employed >72 hours after injury compared to within 72 hours of injury.²² There were no PE events reported in either group. Patients can generally be started on anticoagulant therapies within 72 hours to decrease the risk of DVT.

Cost-Effectiveness

No studies specifically analyzed the cost-effectiveness of DVT/PE prophylaxis in the traumatic SCI population. In patients with acute ischemic stroke, however, Pineo et al reported a lower average anticoagulant cost, including drug-administration costs, in patients treated with UFH (\$259) compared to those who received LMWH (\$360).³⁰ In contrast, total hospital costs, including both clinical events and drug costs, were lower in the LMWH group (\$782) than in the UFH group (\$922). In the traumatic SCI population, there is limited data to suggest superior outcomes of one treatment over another; as a result, direct drug and administration costs may have a larger

impact on decision making. Future cost-effectiveness studies are required to confirm this hypothesis and must consider costs associated with length of stay, adverse events, and drug administration.

Strengths and Limitations

The strength of this systematic review is that it primarily summarizes results from RCTs. Furthermore, studies in all languages were considered for inclusion.

The limitations of this review include (1) poor methodologic quality of included studies, (2) small sample sizes and low event rates, and (3) significant clinical heterogeneity across studies prevented data pooling and meta-analysis (eg, differences in populations, antithrombotic drug and mechanical treatment protocols, diagnostic methods and outcomes).

Conclusions

Prophylactic treatments can be used to lower the risk of VTE events in patients with acute SCI, without significant increase in risk of bleeding and mortality. There were no significant differences in efficacy and safety of different types of LMWH or between LMWH and UFH. Patients should not be treated with adjusted-dose heparin due to significantly a higher risk of bleeding. Prophylaxis should generally be initiated as early as is safe after injury.

Acknowledgments

We would like to acknowledge Dr William Geerts for his thorough external review of this systematic review. We would also like thank Jeffrey Hermsmeyer, BS, for his assistance with literature searching, data abstraction, and critical appraisal of included studies.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by AOSpine and the AANS/CNS Section on Neurotrauma and Critical Care. Dr Fehlings wishes to acknowledge support from the Gerald and Tootsie Halbert Chair in Neural Repair and Regeneration and the DeZwirek Family Foundation. Dr Tetreault acknowledges support from a Krembil Postdoctoral Fellowship Award. Analytic support for this work was provided by Spectrum Research, Inc, with funding from the AOSpine North America.

Supplemental Material

The supplemental material is available in the online version of the article.

References

1. Teasell RW, Hsieh JT, Aubut JA, et al. Venous thromboembolism after spinal cord injury. *Arch Phys Med Rehabil*. 2009;90:232-245. doi:10.1016/j.apmr.2008.09.557.
2. Miranda AR, Hassouna HI. Mechanisms of thrombosis in spinal cord injury. *Hematol Oncol Clin North Am*. 2000;14:401-416.
3. Cheng JS, Arnold PM, Anderson PA, Fischer D, Dettori JR. Anticoagulation risk in spine surgery. *Spine (Phila Pa 1976)*. 2010;35(9 suppl):S117-S124. doi:10.1097/BRS.0b013e3181d833d4.
4. Gerlach R, Raabe A, Beck J, Woszczyk A, Seifert V. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery. *Eur Spine J*. 2004;13:9-13. doi:10.1007/s00586-003-0642-8.
5. Fehlings MG, Wilson JR, Kopjar B, et al. Efficacy and safety of surgical decompression in patients with cervical spondylotic myelopathy: results of the AOSpine North America prospective multicenter study. *J Bone Joint Surg Am*. 2013;95:1651-1658. doi:10.2106/JBJS.L.00589.
6. Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. *J Bone Joint Surg Am*. 2003;85-A:1-3.
7. Skelly AC, Hashimoto RE, Norvell DC, et al. Cervical spondylotic myelopathy: methodological approaches to evaluate the literature and establish best evidence. *Spine (Phila Pa 1976)*. 2013;38(22 suppl 1):S9-S18. doi:10.1097/BRS.0b013e3182a7ebbf.
8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328:1490.
9. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011;64:401-406.
10. Northover JR, Wild JB, Braybrooke J, Blanco J. The epidemiology of cervical spondylotic myelopathy. *Skeletal Radiol*. 2012;41:1543-1546. doi:10.1007/s00256-012-1388-3.
11. West S, King V, Carey TS, et al. *Systems to Rate the Strength of Scientific Evidence* (Evidence Report/Technology Assessment No. 47). Rockville, MD: Agency for Healthcare Research and Quality; 2002.
12. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care Program. *J Clin Epidemiol*. 2010;63:513-523. doi:10.1016/j.jclinepi.2009.03.009.
13. StataCorp. *Stata Statistical Software: Release 9*. College Station, TX: StataCorp LP; 2005.
14. Agarwal NK, Mathur N. Deep vein thrombosis in acute spinal cord injury. *Spinal Cord*. 2009;47:769-772.
15. Chiou-Tan FY, Garza H, Chan KT, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. *Am J Phys Med Rehabil*. 2003;82:678-685.
16. Green D, Lee MY, Ito VY, et al. Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. *JAMA*. 1988;260:1255-1258.
17. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. *Ann Intern Med*. 1990;113:571-574.
18. Green D, Rossi EC, Yao JS, Flinn WR, Spies SM. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf

- compression, aspirin, and dipyridamole. *Paraplegia*. 1982;20:227-234.
19. Merli GJ, Herbison GJ, Ditunno JF, et al. Deep vein thrombosis: prophylaxis in acute spinal cord injured patients. *Arch Phys Med Rehabil*. 1988;69:661-664.
20. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. *J Trauma*. 2003;54:1116-1124.
21. Lohmann U, Glaser E, Braun BE, Botel U. Prevention of thromboembolism in spinal fractures with spinal cord injuries. Standard heparin versus low-molecular-weight heparin in acute paraplegia [in German]. *Zentralbl Chir*. 2001;126:385-390. doi:10.1055/s-2001-14757.
22. Aito S, Pieri A, D'Andrea M, Marcelli F, Cominelli E. Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients. *Spinal Cord*. 2002;40:300-303.
23. Halim TA, Chhabra HS, Arora M, Kumar S. Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an Indian perspective. *Spinal Cord*. 2014;52:547-550. doi:10.1038/sc.2014.71.
24. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. *J Trauma*. 2003;54:1111-1115.
25. Frisbie JH, Sasahara AA. Low dose heparin prophylaxis for deep venous thrombosis in acute spinal cord injury patients: a controlled study. *Paraplegia*. 1981;19:343-346.
26. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood*. 2005;106:2710-2715. doi:10.1182/blood-2005-04-1546.
27. McClendon J Jr, O'Shaughnessy BA, Smith TR, et al. Comprehensive assessment of prophylactic preoperative inferior vena cava filters for major spinal reconstruction in adults. *Spine (Phila Pa 1976)*. 2012;37:1122-1129. doi:10.1097/BRS.0b013e31824abde2.
28. Rodriguez JL, Lopez JM, Proctor MC, et al. Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. *J Trauma*. 1996;40:797-802.
29. Gorman PH, Qadri SF, Rao-Patel A. Prophylactic inferior vena cava (IVC) filter placement may increase the relative risk of deep venous thrombosis after acute spinal cord injury. *J Trauma*. 2009;66:707-712. doi:10.1097/TA.0b013e3181888beba.
30. Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial. *J Hosp Med*. 2012;7:176-182. doi:10.1002/jhm.968.